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Background: To develop a lipid-stabilized contrast formulation containing gadobenate 
dimeglumine for clear visualization of the mucosal surfaces of the larynx and trachea for early 
diagnosis of disease by magnetic resonance imaging.
Methods: The contrast formulation was prepared by loading gadobenate dimeglumine into 
egg phosphotidylcholine, cholesterol, and sterylamine nanoliposomes using the dehydration-
rehydration method. The liposomal contrast formulation was ultrasonically nebulized, and the 
deposition and coating pattern on explanted pig laryngeal and tracheal segments was examined 
by inductively coupled plasma atomic emission spectroscopy. The sizes of the nebulized droplets 
were characterized by photon correlation spectroscopy. The contrast-enhanced mucosal surface 
images of the larynx and trachea were obtained in a 3.0T magnetic resonance scanner using a 
T1-weighted spectral presaturation inversion recovery sequence.
Results: Various cationic liposome formulations were compared for their stabilization effects on 
the droplets containing gadobenate dimeglumine. The liposomes composed of egg phosphotidylcho-
line, cholesterol, and sterylamine in a molar ratio of 1:1:1 were found to enable the most efficient 
nebulization and the resulting droplet sizes were narrowly distributed. They also resulted in the 
most even coating on the laryngeal and tracheal lumen surfaces and produced significant contrast 
enhancement along the mucosal surface. Such contrast enhancement could help clearer visualiza-
tion of several disease states, such as intraluminal protrusions, submucosal nodules, and craters.
Conclusion: This lipid-stabilized magnetic resonance imaging contrast formulation may be 
useful for improving mucosal surface visualization and early diagnosis of disease originating 
in the mucosal surfaces of the larynx and trachea.
Keywords: lipid, gadolinium, magnetic resonance imaging, upper airway, nebulization, 
mucoadhesion
Introduction
There are many diseases that involve abnormalities occurring on the mucosal surfaces of 
the larynx and trachea.1 Among them, squamous cancer of the larynx is the most commonly 
occurring head and neck cancer.2 In addition, neoplasms involving the mucosal surfaces 
of the trachea are also abundant, but easily   misdiagnosed as bronchitis or asthma because 
of a lack of specific symptoms.3 Endoscopic   examination has been widely used to detect 
these mucosal abnormalities. However, disease-related submucosal spread and infiltration 
into the surrounding tissues are not visible at endoscopy.1 Some bulky tumors are also 
reported to hinder distal endoscopic   visualization, particularly in the subglottic region.4 
As a complementary tool, cross-sectional imaging methods, such as magnetic resonance 
imaging (MRI) may be used to detect abnormal soft tissue thickening and cartilage inva-
sion or fat infiltration, and thus help in accurate depiction of the disease state.2,4,5International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Although MRI has excellent soft tissue contrast, the 
imaging qualities of the lung and airway have always been 
poor. The low proton density of the airway and pulmonary 
parenchyma results in low signal-to-noise ratios.6 In addi-
tion, complex air-soft tissue interfaces produce an inho-
mogeneous magnetic field for imaging, and artifacts are 
  common.6 In order to improve the quality of MRI in the 
airway,   researchers had used hyperpolarized gas, such as 3He7 
or 129Xe,8 or nebulized gadolinium solutions.9 However, these 
agents were designed mainly to evaluate lung ventilation 
and do not deposit on the lumen surfaces. Therefore, it has 
been difficult to visualize the mucosal surfaces using MRI.2 
To address this problem, we developed a contrast formulation 
that can coat the mucosal surfaces of the larynx and trachea 
evenly, thus helping visualization and detection of small foci 
in early stages of disease development.
Mucoadhesive systems have been widely used for 
intranasal,10 buccal,11 peroral,12,13 and airway14,15 drug 
  delivery. Longer retention of drugs adhering to mucosal 
surfaces has been shown to improve in situ or systemic 
therapeutic effects significantly. The most commonly used 
mucoadhesive   excipients are hydrophilic macromolecules, 
such as carbomers,16 sodium alginate,11 chitosan,15 and 
  cellulose derivatives.17 However, these can be highly viscous 
and unsuitable for airway administration. In some recent 
research, cationic lipids were also shown to promote   adhesion 
through interactions between cationic vehicles and the 
  negatively charged mucosal surface.18 Lipids are also useful 
for modulating the aerodynamic diameters of nebulized 
droplets for optimal distribution in the respiratory tract and 
deposition on the laryngeal and tracheal surfaces.19 In this 
study, in order to achieve even coating of the mucosal surfaces, 
we included egg phosphotidylcholine and cholesterol in a 
formulation for stabilizing gadobenate dimeglumine droplets, 
and added stearylamine to improve mucoadhesiveness. The 
formulations were optimized to provide significant and even 
imaging contrast enhancement of the mucosal surfaces.
Materials and methods
Materials
Egg phosphatidylcholine of 99% purity was purchased from 
Lipoid GmbH (Ludwigshafen, Germany), and cholesterol 
and stearylamine of 97% and 99% purity, respectively, were 
purchased from Sigma-Aldrich Co Ltd (St Louis, MO). 
  Gadobenate dimeglumine injection (MultiHance®) was 
obtained from Shanghai Bracco Sine Pharmaceutical Corpo-
ration Ltd (Shanghai, China). The other reagents used in this 
study were of analytical grade and purchased from Shanghai 
Chemical Reagent Co Ltd (Shanghai, China).
Preparation of lipid-stabilized contrast 
formulation
The lipid-stabilized contrast agent was prepared by 
lyophilization-rehydration. Egg phosphatidylcholine, 
sterylamine, and cholesterol in different ratios were dissolved 
in tert-butanol. MultiHance injection was slowly added to 
the lipid solution and mixed well. The resulting transparent 
  solutions were dispersed in vials and lyophilized (0.100 mbar, 
36–48 hours). The lipid-stabilized contrast formulations were 
obtained by rehydration of the lyophilized powder with water 
for injection in 50°C to a concentration of 12 mg Gd/mL, 
and homogenized in an ultrasonic water bath.
Measurement of particle size and zeta 
potential
The particle size and zeta potential of the gadobenate 
  dimeglumine encapsulated/complexed liposomes were 
  measured by photon correlation spectroscopy (Zetasizer 
3000HSa, Malvern, Worcestershire, UK) at 25°C. The 
  samples were diluted with deionized water. The measure-
ments were carried out three times and the results were 
averaged.
Nebulization of lipid-stabilized contrast 
formulations
The lipid-stabilized contrast formulations in 30 mL 
  volume were put into an ultrasonic nebulizer (YUYUE402, 
  Shanghai Medical Instrument Company, Shanghai, China) 
and   nebulized using the following parameters: frequency 
1.5 mHz, water bath temperature 50°C, nebulization volume 
4 mL/min, and medium airstream flow.
Measurement of droplet size of nebulized 
contrast formulations
The droplet sizes of the nebulized lipid-stabilized contrast 
formulations were measured using a Spraytec RTSizer 
(Malvern) at room temperature in auto mode. The measure-
ment parameters were: path length 12.00 mm, scattering 
rings 3–31, size bins 0–59, and mesh factor 1, with multiple 
scattering enabled. Diluted MultiHance injection in the same 
concentration (12 mg Gd/mL) was used as the control.
Preparation of explanted pig larynx and 
trachea segments
Freshly explanted pig tracheas with an intact larynx were 
ordered from a slaughter house. The blood on the segments 
was carefully cleaned with cotton balls and the tracheas were 
cut to be around 30 cm in length.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Three diseased tissue models with representative mucosal 
abnormalities were prepared. The intraluminal protrusion 
model was prepared by implanting three lean pork balls with 
diameters of 5 mm, 10 mm, and 15 mm inside the tracheal 
lumen. The submucosal nodule model was prepared by injec-
tion of 1% methyl cellulose under the tracheal mucosal surface 
to form “lumps” of about 3 mm, 5 mm, and 8 mm in diameter, 
respectively. For preparation of the submucosal crater lesion 
model, a small area of tracheal tissue was resected to about 
1–2 mm in depth, and then the tracheal tissue was sewn up.
characterization of contrast agent 
deposition on luminal surface
The lipid-stabilized contrast formulations were nebulized 
and delivered to the horizontally placed ex vivo pig tracheal 
segments from the direction of the larynx. The tracheas were 
stretched softly during delivery. For each trachea, nebuliza-
tion delivery lasted for two minutes. Diluted MultiHance 
injection in the same concentration (12 mg Gd/mL) was 
nebulized for the comparison.
After nebulization delivery, the pig tracheal segments 
were cut open horizontally and divided into top half and 
bottom half segments (Figure 1). Each half segment was 
further divided into three areas, based on their distances to 
the larynx, ie, the proximal area (3 cm to the larynx), the 
middle area (15 cm to the larynx), and the distal area (27 cm 
to the larynx). For each area, a 1 cm2 trachea sample in a 
square shape was collected. The samples were homogenized 
and treated with nitric acid. Gadolinium concentrations 
in each tracheal sample were measured using inductively 
coupled plasma atomic emission spectroscopy (IRIS/AP, 
Thermo Fisher Scientific, Waltham, MA).
Magnetic resonance imaging of larynx  
and trachea
The nebulized lipid-stabilized contrast formulation was 
delivered to the ex vivo pig tracheal segments using the same 
method as described earlier. The tracheal samples were num-
bered and enwrapped inside fresh lean meat to eliminate the 
interference of air on imaging. MRI   examination of the tracheas 
before and after contrast agent delivery was performed on a 
Philips Intera Achieva 3.0 Tesla MR scanner (Philips, The 
Netherlands) with a SENSE head loop using a T1-weighted 
spectral presaturation inversion recovery sequence.
statistical analysis
The data were presented as the mean ± standard deviation. 
Statistical analysis was performed using the Student’s t-test, 
and differences were judged to be significant at P , 0.05.
Results
Preparation and characterization of 
lipid-stabilized contrast formulation
We determined in preliminary studies that gadolinium con-
centrations in the range of 6–12 mg/mL were optimal for 
contrast enhancement on mucosal surfaces. Based on this 
concentration, four different lipid formulations were designed 
(Table 1) and prepared by the lyophilization-rehydration 
method. After rehydration, while some of the gadobenate 
dimeglumine molecules could be encapsulated, some could 
be simply adsorbed onto the liposome surfaces due to the 
excessive amount of negative ions of gadobenic acid. The 
resulting liposomes had mean particle sizes of around 
200 nm. The zeta potentials ranged from -39 to -64 mV .
Nebulization of lipid-stabilized contrast 
formulation
The liposomal contrast solution was nebulized by 
  ultrasonication. The sizes of the resulting droplets were 
measured using a Spraytec RTSizer based on the laser dif-
fraction method. As shown in Figure 2A, for all the five 
groups, droplets with a volume mean diameter D (4,3) of 
around 5–7 µm suitable for upper airway deposition were 
generated via ultrasonic nebulization. However, the size 
distribution was affected considerably by the lipid compo-
nents. The lipid-stabilized droplets had much smaller Dv10 
and Dv90 diameters than that of the control (Figure 2A), 
and concentrated in only one peak in the cumulative volume 
percent curve except for L4 (Figure 2B). The results suggest 
that the lipid components were helpful for generation and sta-
bilization of small and uniform droplets during nebulization. 
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Figure 1 schematic illustration of the sampling operation for the deposition study 
of nebulized lipid-stabilized contrast agent on the luminal surface of ex vivo pig 
laryngeal and tracheal segments.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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In addition, increasing the ratio of sterylamine in the lipid 
formulation seemed to have a further stabilization effect for 
the smaller droplets (Figure 2C). More droplets smaller than 
2.15 µm were observed for formulation L1 (33% sterylamine) 
compared with formulation L2 (20% sterylamine). Formula-
tion L3 with 50% sterylamine also produced more smaller 
droplets after nebulization considering that the total lipids 
(25 mg/mL) were less in the formulation. In comparison, the 
L4 formulation free of sterylamine produced larger droplets 
after ultrasonic nebulization and two different size peaks were 
detected. For the control, the droplets were generally bigger, 
without the stabilization effects of the lipids.
Deposition of nebulized contrast 
formulations on lumen surface of pig 
trachea
Deposition of the nebulized contrast formulations on the 
mucosal surface of the larynx and trachea was studied 
Table 1 Particle sizes and zeta potentials of the lipid-stabilized contrast agents
Formulations 
(in molar ratio)
Total lipid concentration  
(mg/mL)
SA to Gd  
(molar ratio)
Size (nm) Zeta potential   
(mV)
(L1) ePc:cholesterol:sA = 1:1:1 32 1:1 182.58 ± 13.35 -38.7 ± 16.4
(L2) ePc:cholesterol:sA = 2:2:1 29 1:2 176.25 ± 13.24 -58.7 ± 22.3
(L3) ePc:cholesterol:sA = 1:1:2 19 1:1 181.58 ± 15.28 -31.5 ± 9.9
(L4) ePc:cholesterol = 1:1 26 No sA 169.42 ± 11.30 -63.4 ± 16.3
Abbreviations: ePc, egg phosphotidylcholine; sA, sterylamine; gd, gadolinium.
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Figure 2 Average diameter (A), diameter distribution (B), and percentage of small droplets (C) of lipid-stabilized droplets and the control after ultrasonic nebulization. In 
B, the blue columns represent the volume frequency percentage and the red curve represents the cumulative volume percentage; in the cumulative volume overlay graph, 
pink indicates L1, black indicates L2, green indicates L3, blue indicates L4 and red indicates the control.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 3 gadolinium concentrations at different sites on pig tracheal luminal surfaces after nebulization delivery of lipid-stabilized contrast agent and the control.
by measuring gadolinium concentrations at different 
sampling sites using inductively coupled plasma atomic 
emission spectroscopy. As shown in Figure 3, the addition 
of sterylamine to the formulation greatly improved the 
deposition of gadolinium at the top luminal surfaces. 
Gadolinium concentrations from L1, L2, and L3 reached on 
the top half of the trachea lumen were significantly higher 
than that from L4 and the control. At the same time, more 
lipid-stabilized droplets successfully distributed to the distal 
segments. As a comparison, the droplets of the control and L4 
formulations accumulated mainly in the bottom parts of the 
tracheas in the proximal segment just adjacent to the larynx, 
and gadolinium concentrations decreased significantly with 
distance. Of the four lipid-stabilized contrast agents, the L1 
formulation showed the most even deposition on the tracheal 
mucosal surface. It was therefore used in the MRI study.
MrI study of larynx and tracheal lumen 
surface
The lipid-stabilized gadobenate dimeglumine formulation, 
L1, was nebulized and delivered to the freshly explanted 
pig trachea segments. The mucosal surface visualization 
effect was evaluated. In imaging sequence screening, the 
T1 weighted-spectral presaturation inversion recovery 
sequence showed the best visualization effect and was used 
in the MRI studies. As shown in Figure 4, even contrast 
enhancement on the laryngeal and tracheal mucosal surface 
was achieved with the lipid-stabilized contrast formulation. 
The mucosal surfaces were effectively “lightened up” with an 
even coating of gadolinium and were very clearly visualized. 
The bright signals along the lumen surface in both the larynx 
and trachea was generally uniform, as shown in the transverse 
images of different layers in successive scanning (Figure 5). 
In   comparison, only parts of the larynx and tracheas (especially 
the areas in the bottom half of the lumens) were effectively 
contrasted with the control (Figure 4B1 and B2).
The mucosal surface visualization effect of the lipid-
stabilized contrast formulation was further evaluated in the 
three diseased tissue models (Figure 6A and B). With the 
nebulized lipid-stabilized contrast formulation, the small 
intraluminal protrusion and the submucosal nodule were 
clearly depicted with bright signals. In Figure 6C, one small 
crater (as pointed out by the arrow) on the luminal surface 
was also clearly visualized.
Discussion
MRI has been proven to be very useful in the diagnosis 
of laryngeal and tracheal tumors because of excellent soft 
  tissue contrast and high sensitivity to cartilaginous   invasion. 
  However, due to the very low proton density and large International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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air-soft tissue interfaces in the airway, visualization of the 
mucosal surfaces by MRI is not satisfactory. Small foci or 
alternations on the mucosal surface are reported to be hard 
to detect or invisible.2 Because most malignant laryngeal 
and tracheal tumors occur in the epithelium with alterations 
on the mucosal surface, we tried to improve the sensitivity 
of MRI for early detection of mucosal lesions by direct clear 
visualization of the mucosal surfaces. In order to enhance the 
signals on the mucosal surface, we designed a lipid-stabilized 
formulation for a gadolinium contrast agent. The nebulized 
contrast formulation could coat evenly on the mucosal   surface, 
and light up the surface for MRI. Some earlier   studies have 
used aerosolized gadolinium solutions to   evaluate pulmonary 
ventilation,9,20–22 but there has been no report on mucosal 
coating contrast agents specifically designed to visualize the 
laryngeal and tracheal surfaces for MRI.
In order to achieve an even coating effect on the laryn-
geal and tracheal mucosal surfaces for imaging, we selected 
lipids as the stabilization and mucoadhesion agent. Lipids 
and liposomes have been widely used for pulmonary 
  delivery of therapeutic proteins or chemical compounds.23–25 
In recent years, cationic liposome systems were developed 
for improved gene delivery to airway mucosal surfaces.18,26,27 
Compared with other materials, such as polymers, lipids have 
good safety and biocompatibility. Therefore, we used egg 
A1
A2
B1
A: The liposomeB : The control
B2
Figure 4 Transverse magnetic resonance images of ex vivo pig laryngeal (A1 and B1) 
and tracheal (A2 and B2) segments before and after nebulization delivery of lipid-
stabilized contrast agent and the control. Left images, before nebulization; right 
images, after nebulization.
Figure 6 Transverse magnetic resonance images of three diseased tissue models 
before (left column) and after (right column) contrast enhancement by the nebulized 
lipid-stabilized contrast formulation. (A) Intraluminal protrusion, (B) submucosal 
nodule, and (C) submucosal crater.
Figure 5 Transverse magnetic resonance images of ex vivo pig laryngeal and tracheal lumen in successive scanning layers after nebulization delivery of the lipid-stabilized 
contrast agent. In each image, the left is the larynx, and the right is the tracheal lumen.
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phosphatidylcholine as the main lipid component for forma-
tion of fluid phase membrane vesicles, and cholesterol in high 
molar ratios ranging from 25% to 50% was included.
We included sterylamine in the formulations to improve 
the mucoadhesive effect of the droplets. The mucosal surface 
is covered by a thin layer of mucus, with major components 
of mucin glycoproteins, lipids, inorganic salts, and water.28 
Because most mucin glycoproteins have a strongly negatively 
charged surface due to a high sialic acid and sulfate content,29 
various positively charged materials could be used to enhance 
the electric interactions with the mucosal surface28 and help 
the vehicles to adhere to the mucosal surface effectively. In 
our study, sterylamine was positively charged at neutral pH, 
and its single fatty acid chain could easily insert into the 
phospholipid bilayers.
The gadolinium agent was loaded into the lipid vehicles 
using the lyophilization-rehydration method, and particles 
with a mean diameter of about 200 nm were generated. 
Interestingly, the particles were negatively charged, with 
zeta potentials ranging from -39 mV to -64 mV . We believe 
this to be because of the excessive negative charges in the 
gadobenate dimeglumine molecules adsorbed on the vehicle 
surfaces. As a rather toxic ion, gadolinium in free form (Gd3+) 
must be chelated to form a stable complex for in vivo imaging 
applications. For gadobenate dimeglumine, the gadolinium 
ion is chelated with 4-carboxy-5,8,11-tris(carboxymethyl)-
1-phenyl-2-oxa-5,8,11-triazatridecan-13-oic acid to form 
gadobenic acid [Gd(bopta)(H2O)]2-.30 The two extra negative 
charges on each gadobenic acid molecule may interact with 
the positively charged amine of sterylamine and create a 
negatively charged surface. Therefore, the particles had 
negative zeta potentials.
In addition to mucoadhesive properties, the droplets 
should also be of a suitable size range for effective deposition 
on the laryngeal and tracheal mucosal surface. Deposition of 
nebulized droplets in the respiratory tract was significantly 
affected by their sizes. Droplets larger than 5 µm would 
impact on the larynx and pharynx after inhalation. Droplets 
with diameters of 0.5–5 µm would sediment in the airway, and 
droplets smaller than 0.5 µm would be in Brownian motion 
and settle very slowly in the airway lumen.19 In our study, 
we characterized the sizes of nebulized droplets stabilized 
with various lipid formulations using the laser diffraction 
method. This method has been used in aerosol formulation 
studies and proven to be a very fast and highly reliable tech-
nique.31 Compared with the more commonly used cascade 
impactor analysis, the size distributions measured by the laser 
  diffraction method are independent of the flow rate and could 
be automatically recorded as a function of inhalation time.31 
As shown in Figure 2A, the mean volume diameter of the 
droplets was around 4–6 µm. As expected, the amphiphilic 
lipid components effectively helped to   generate droplets in 
a narrow size distribution.
Deposition of the nebulized droplets on the mucosal 
surface of the trachea was studied by measuring gadolinium 
concentrations at different sites in the lumen. In order to 
evaluate the mucoadhesive effect of the droplets, we positioned 
the pig tracheal segments horizontally during nebulization 
delivery, then cut them open vertically to compare deposits 
on the top and bottom segments. The delivery time was set 
to be two minutes to ensure effective coating without droplet 
coagulation or flowing on the surface. As shown in Figure 3, 
in all the groups, gadolinium concentrations in the bottom 
half of the mucosal surface of the trachea were always higher 
than those at the top half, in part due to the gravity effect. 
However, the three lipid formulations containing sterylamine 
(L1, L2, and L3) effectively improved adsorption of droplets 
to the top half of the mucosal surface. According to Smart,28 
the mucoadhesion process would include two steps, ie, 
contact and consolidation. The droplets or particles would 
firstly come into intimate contact with the mucosal surface, 
and then a strengthened adhesive joint would form through 
various physicochemical interactions, leading to a prolonged 
adhesion effect. On this basis, we believe that the improved 
deposition profiles of the three lipid-stabilized droplets may 
be attributable to the amphiphilic properties of the lipids and 
the positive surface charges on the cationic lipid, sterylamine. 
The presence of amphiphilic lipids would improve contact 
of the droplets with the mucosal surface by decreasing the 
surface energy of the droplets. The adhesive process was 
further consolidated by the charge interactions between 
the positively charged sterylamine and negatively charged 
mucosal surface.
We also believe that the smaller droplets in the three for-
mulations helped their mucoadhesion. As shown in Figure 2C, 
the addition of sterylamine resulted in smaller droplets with a 
diameter of less than 2.15 µm after nebulization. The smaller 
droplets with large surface area to volume ratios and higher 
attractive forces28 would move in the lumen with the direction 
of the airstream and adhere to the mucosal surface whenever 
the interactions were strong enough. We noticed that in the 
proximal parts of the lumen where the gas flow changed 
dramatically due to the cross-sectional diameter moving from 
the larynx to the trachea,32 the smaller particles seemed to 
have more chance to interact with the mucosal surface, and 
better deposition was observed for L2 and L3. For the same International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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reason, in the distal part at the end of the tracheal segments, 
better deposition by L2 and L3 was also achieved. Therefore, 
we think the improved deposition effect of L1 was not merely 
due to the presence of sterylamine in the formulation. The 
lipid ratios and total amounts of lipid also played an important 
role in the generation, stabilization, and mucoadhesion of the 
droplets via nebulization.
For the formulations free of sterylamine, the droplets 
mainly deposited in the bottom half of the mucosal surfaces 
of the trachea, and gadolinium concentrations were much 
higher on the proximal surface. This is probably because of 
the larger droplets in these two groups. The medium-sized 
droplets were more likely to deposit onto the middle and distal 
areas along the tracheal lumen. It should be noticed that the 
amount of gadolinium delivered with the L4 formulation and 
the control was much higher than that with the other three 
lipid groups. This could be explained by the higher nebuliza-
tion efficiency of L4 and the control due to their relatively 
low viscosities in the five groups. There were more droplets 
obtained for the group with low viscosity (the droplet volume 
concentrations for L1, L4, and the control were 7.4, 25.3, and 
77.0 ppm, respectively).
In the MRI study, the mucosal surface of freshly 
explanted pig laryngeal and tracheal segments was very 
clearly visualized using the lipid-stabilized contrast agent. 
The mucosal surface was outlined smoothly and evenly with 
bright signals. Considering the complex anatomic structures 
in the larynx and the complicated gas flows in the upper 
airway, the even coating and contrast enhancement with the 
nebulized agent was a significant improvement. We further 
evaluated the   visualization effects for three common airway 
lesions. The shapes and locations of all the representative 
tissue abnormalities were successfully depicted. These 
preliminary results suggest that a lipid-stabilized contrast 
agent would be beneficial for improvement of MRI in early 
diagnosis of diseases of the larynx and trachea.
Conclusion
In this study, a liposomal gadobenate dimeglumine contrast 
formulation was successfully developed for clear MRI 
  visualization of the mucosal surface on the larynx and trachea 
via nebulization. Various cationic liposome formulations 
were compared for their stabilization effects on gadobenate 
dimeglumine-containing droplets. Liposomes composed of 
egg phosphotidylcholine, cholesterol, and stearylamine in a 
molar ratio of 1:1:1 were found to have the most efficient 
nebulization effect, and had the most narrowly distributed 
droplet sizes. The nebulized droplets were of mean diameter 
4–6 µm after ultrasonic nebulization. They evenly coated 
on the laryngeal and tracheal lumen surfaces and produced 
significant contrast enhancement along the mucosal surface. 
Such contrast enhancement enabled clearer visualization 
of several disease states, such as intraluminal protrusions, 
submucosal nodules, and craters in ex vivo pig laryngeal and 
tracheal segments. The liposomal MRI contrast formulation 
may be useful for improving visualization of the mucosal 
surface and early diagnosis of diseases originating from the 
mucosal surfaces of the larynx and trachea.
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